Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
The biopharmaceutical sector finally regained its footing in 2025. Here are 5 issues that could determine whether the renewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback